Company Description
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia.
It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform.
The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Country | United Kingdom |
| Founded | 2020 |
| IPO Date | May 28, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Mario Accardi |
Contact Details
Address: 1 Ashley Road, 3rd Floor Altrincham, WA14 2DT United Kingdom | |
| Website | centessa.com |
Stock Details
| Ticker Symbol | CNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 1847903 |
| CUSIP Number | 152309100 |
| ISIN Number | US1523091007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mario Alberto Accardi Ph.D. | Chief Executive Officer and Director |
| Iqbal J. Hussain L.L.B. | Chief Legal Officer, Chief Compliance Officer and Company Secretary |
| Tia L. Bush | Chief Technology and Quality Officer |
| Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations and Corporate Communications |
| Karen M. Anderson | Chief People Officer |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Charlene Stoudt | Senior Vice President of Clinical Development Operations |
| Dr. Stephen J. Kanes M.D., Ph.D. | Head of Research & Development and Chief Medical Officer |
| Dr. Kimberly A. McCormick Pharm.D. | Senior Vice President of Regulatory Affairs and Medical Writing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2026 | PREM14A | Filing |
| Apr 13, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | 8-K | Current Report |